Short answer
Adaptive Biotechnologies Corp (ADPT) filed an 8-K current report with the SEC on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Press release covers Adaptive Biotechnologies’ quarter ended September 30, 2026.
Adaptive Biotechnologies Corp 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Press release covers Adaptive Biotechnologies’ quarter ended September 30, 2026
- Financial results and management commentary are in Exhibit 99.1
- Investor focus: quarterly performance, cash position and forward outlook in the attached release
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $83.9M, down 11% year over year, but excluding Genentech milestone effects, revenue increased 39%
- MRD revenue $72.6M, up 28%, with clonoSEQ testing volume up 46% to 39,587 tests
- Total-company adjusted EBITDA $14.3M and free cash flow $7.7M, marking quarterly profitability ahead of expectations
- MRD adjusted EBITDA $15.1M versus $7.0M, while Immune Medicine revenue fell 70% to $11.3M
- 2026 MRD revenue guidance raised to $276M-$286M, implying 30%-35% growth, with operating-expense guidance reduced to approximately $350M
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Adaptive Biotechnologies Corp 8-K filings
Get the next ADPT 8-K as it lands
Follow ADPT for push alerts, or ask the research agent what this filing means.